SOPHiA GENETICS proudly stepped up as a founding member of #CancerX in Washington, DC. Alongside over 125 other organizations, we participated in the inaugural meeting, opening a new chapter in the fight against cancer. The White House is spearheading ambitious plans to fight against cancer. Among 17 bold initiatives under the Cancer Moonshot program, CancerX stands out, being the only initiative leveraging the full potential of #digitalinnovation. SOPHiA GENETICS is honored to contribute to turning this vision into reality. 📍 Follow us for updates on this exciting path we’re paving! https://lnkd.in/dwWJZ7qm
Join us at the NASDAQ Headquarters for the "AI-Driven Precision Oncology Summit" on September 26, 2023, where we will unveil the potential of data-driven innovation.
SOPHiA GENETICS is pleased to announce its Q2 2023 financial results. Highlights from this quarterly report include: - 29% revenue growth YoY on a reported basis - Record platform analysis volume, up 27% YoY* - Continued customer traction, including Tulane University School of Medicine based in the U.S., just announced today - Strong gross margins at 67% - Continued financial discipline resulting in meaningful expense reductions and improved cash flow 📌 Read more in our full earnings press release here:
